Genmab Holding B.v.

Martine E D Chamuleau

Paul Parren

Frank Beurskens

Esther Breij

Simone Oostindie

Hilma Van Der Horst

Tuna Mutis

Ronald P Taylor

Margaret A Lindorfer

Marije Overdijk

Andreas Hollenstein

Edward Norbert Van Den Brink

Ronald Taylor

CD37-specific bispecific antibody molecules binding to different epitopes of the human CD37 antigen which bispecific antibody molecules have enhanced Fc-Fc interactions upon binding to CD37 on the cell surface. The invention also relates to the monoclonal parental antibodies from which the first or the second binding region of the bispecific antibody molecules is obtained. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer and other diseases using these compositions.

Bispecific anti-CD37 antibodies, monoclonal anti-CD37 antibodies and methods of use thereof

The present invention relates to anti-CD37antibodies having an Fc-Fc interaction enhancing substitution in the Fc-region of a human IgG, for use as a medicament in combination with anti-CD20 antibodies having an Fc-Fc interaction enhancing substitution in the Fc-region of a human IgG. The invention also relates to a novel composition of anti-CD37 antibodies having an Fc-Fc 5 interaction enhancing substitution and anti-CD20 antibodies having an Fc-Fc interaction enhancing substitution. In particular, the invention relates to compositions wherein the anti-CD37 antibody binds human CD37 and the anti-CD20 antibody binds human CD20. The invention also relates to compositions where the composition is a pharmaceutical composition and the use of such compositions in treatment of cancer and other diseases.

Anti-CD37 antibodies and anti-CD20 antibodies, compositions and methods of use thereof

Growing community of inventors

Amsterdam, Netherlands

Martine E D Chamuleau